4009.SR
Unloved QualityMiddle East Healthcare Company · Healthcare · Saudi Arabia · $563M cap · $2.1M/day traded
SAR 22.95 -0.8% · close 5 Nov · scored 7 Nov
Unloved Quality: Strong and cheap, but the market has not warmed to it.
As of 7 Nov 2026, the MoatMap Score for Middle East Healthcare Company (4009.SR) is 73/100, ranked against 25,000+ stocks in 38 markets (Quality 57, Value 68, Momentum 44, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT MIDDLE EAST HEALTHCARE COMPANY
Read
Middle East Healthcare Company, a healthcare provider, owns and operates a network of hospitals under the Saudi German Hospital name in the Kingdom of Saudi Arabia and internationally.
FINANCIAL SUMMARY (SAR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.7B | 2.9B | 3.1B | 13.0% | 3.3B | 3.4B | 3.7B | 8.9% |
| EPS (SAR) | 0.82 | 0.19 | 3.06 | 3.28 | 58.7% | 1.64 | 1.88 | 2.16 | -18.9% |
| Shares | 92.0M | 92.0M | 92.0M | 92.0M | 0.0% | 92.0M | — | — | — |
| Debt | 2.2B | 2.5B | 2.5B | 2.5B | 4.3% | 2.6B | — | — | — |
| Equity | 1.3B | 1.3B | 1.6B | 1.9B | 12.1% | — | — | — | — |
| Op CF | 76.0M | 191.1M | 766.0M | 544.6M | 92.8% | 737.6M | — | — | — |
| Inv CF | -249.4M | -242.0M | -508.8M | -338.4M | — | — | — | — | — |
| Fin CF | 160.8M | 78.0M | -256.1M | -229.1M | — | — | — | — | — |
Made a new 52-week low 9 trading days ago, 52% below its 52-week high. The fall has not stopped yet.
Calmer than 65% of stocks we rank over the past year (volatility 34% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4009.SR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| 4009.SR | Middle East Healthcare Company(you) | $563M | 73 |
| 4019.SR | Specialized Medical Company | $875M | 69 |
| 4007.SR | Al Hammadi Holding Company | $925M | 68 |
| 4005.SR | National Medical Care Company | $1.2B | 62 |
| 9546.SR | Naba Al Saha Medical Services Company | $123M | 65 |
| 9530.SR | Arabian International Healthcare Holding Company | $87M | 75 |
| 4002.SR | Mouwasat Medical Services Company | $2.9B | 85 |
| 9594.SR | Al-Modawat Specialized Medical Company | $75M | 68 |
| 9544.SR | Future Care Trading Co. | $161M | 50 |
| 4021.SR | Canadian General Medical Center Complex Company | $92M | 60 |
Peer medians: ROE 13.9% · P/E 16.3x · Gross margin 31.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.